Behzad Kharabi, MD
Dr. Kharabi brings more than 20 years of academic, clinical, and global drug development experience to 3T, including various roles with increasing responsibility at Janssen Pharmaceuticals, Kite Pharmaceuticals/Gilead Sciences, and T-Knife Therapeutics. He led the clinical development for TECARTUS® (brexucabtagene autoleucel), a CD19-directed CAR-T cell therapy used to treat certain blood cancers. Prior to joining the pharmaceutical industry, he served as an independent research investigator at the University Hospital of Aachen, Germany, where he received several research awards and grants including the prestigious Ernst-Jung Award for junior investigators. Dr. Kharabi earned a medical degree from the University of Muenster, Germany and completed research appointments at internally renowned institutes such as Memorial Sloan Kettering Cancer Center and the University of California, San Francisco.
